Clinical Trials Directory

Trials / Completed

CompletedNCT05044598

RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy

RAFT - First in Human Phase I/II Clinical Trial of RAFT for Aniridia Related Keratopathy

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
9 (actual)
Sponsor
University College, London · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The RAFT trial is a first in human trial of a novel cellular therapy called RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) developed and manufactured by Cells for Sight Stem Cell Therapy Research Unit at UCL institute of Ophthalmology. The aim of this seamless phase I/II single-dose, single-arm trial is to investigate if RAFT-OS is a safe and effective alternative treatment for patients with aniridia related keratopathy (ARK) in 21 patients. ARK is a complication of aniridia, which is a genetic eye condition present from birth. RAFT-OS is an artificial tissue, populated with limbal epithelial cells and stromal cells. The source of the adult limbal and stromal cells is from donated human corneas from the NHS blood and Transplant, Tissue and Eye services in Liverpool. Following a Screening visit, participants will commence 10-weeks of immune suppression therapy to prepare for the transplantation of RAFT-OS. The RAFT-OS will be transplanted into the participants worst affected eye. Following surgery, each participant will be assessed at days 1, 7, 14, 21, and 1-month for major or intermediate safety events. Participants will continue to be followed up to 12 months after transplantation and will be required to stay on the immune suppression therapy for the duration of the trial. The trial is conducted at Moorfields Eye Hospital NHS Foundation Trust (MEH), London in the United Kingdom (UK). MEH is a leading provider of eye health services in the UK and is a world-class centre of excellence for ophthalmic research and education. All trial medical assessments and procedures will be performed in an appropriate clinical setting by suitability qualified staff.

Conditions

Interventions

TypeNameDescription
OTHERRAFT-OSRAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.

Timeline

Start date
2021-07-28
Primary completion
2025-04-17
Completion
2025-04-17
First posted
2021-09-16
Last updated
2025-04-30

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05044598. Inclusion in this directory is not an endorsement.